AZN logo
AstraZeneca PLC
AZN
174.35 (-0.60%) 1.05
Market cap
$270.42(B)
Earnings date
Feb-09-2027
Category
Sector
Health Care
Industry
Pharmaceuticals
AstraZeneca PLC a biopharmaceutical company focuses on the discovery development manufacture and commercialization of prescription medicines. The company offers Imjudo Datroway Iressa Tagrisso Imfinzi Lynparza Calquence Enhertu Orpathys Truqap Zoladex Faslodex Crestor Andexxa Onglyza Symlin XIGDUO XR Atacand Atacand HCT Atacand Plus Farxiga/Forxiga Plendil Modip Splendil Munobal Flodil Tenormin Tenormine Prenormine Atenol Zestril Brilinta/Brilique Komboglyze Qtern Wainua Byetta Lokelma Seloken ZOK Toprol-XL Betaloc ZOK XIGDUO Accolate Accoleit Vanticon Bricanyl Respules Eklira Genuair/Tudorza/Bretaris Pulmicort Turbuhaler Symbicort Turbuhaler Airsupra Bricanyl Turbuhaler Fasenra Rhinocort Tezspire Bevespi Aerosphere Daliresp/Daxas Oxis Turbuhaler Saphnelo Breztri Aerosphere Duaklir Genuair Pulmicort Respules and Symbicort pMDI. It also provides Beyfortus Kavigale Evusheld Fluenz/FluMist Synagis Kanuma Ultomiris Koselugo Voydeya Soliris Strensiq Nexium and other medicines. The company offers its products for ocology cardiovascular renal and metabolism respiratory & immunology vaccines and immune and therapies for rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom USA rest of Europe Asia Africa and Australasia. It has a strategic agreement with Tempus and Pathos to develop the multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of oral candidates; Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates; and Carterra Inc. to advances lab-in-the-loop drug discovery through new scientific research collaboration. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is based in Cambridge the United Kingdom.
EV: $339.72(B)
Total Equity: $51.81(B)
Debt/Equity: 0.66
Dividend/share: $3.2
Div. yield: 1.85%
P/E: 24.49
Forward P/E: 17.09
P/FCF: 26.50
P/S: 4.33
P/B: 5.23
EPS: $7.1
EPS (fwd): $10.2
FCF/share: $6.6
Revenue/share: $40.3
Book value/share: $33.4
ROIC: 12.5%
ROA: 8.6%
ROE: 21.7%
Margins: Gross | Op. | Net
81.8% | 22.0% | 17.7%
0.0%of Portfolio
My holdings
Day change
Total change

Growth Estimates

Revenue

CAGR5.5%
TTMFY+1FY+2FY+3FY+4FY+5
TTM
$62.38(B)
FY+1
25
2%
$63.38(B)
FY+2
25
6%
$67.42(B)
FY+3
23
6%
$71.49(B)
FY+4
14
7%
$76.18(B)
FY+5
15
7%
$81.45(B)

Net Income

CAGR17.4%
TTMFY+1FY+2FY+3FY+4FY+5
TTM
$11.03(B)
FY+1
22
44%
$15.86(B)
FY+2
22
12%
$17.70(B)
FY+3
19
11%
$19.60(B)
FY+4
10
14%
$22.43(B)
FY+5
9
10%
$24.61(B)

EPS

CAGR17.7%
TTMFY+1FY+2FY+3FY+4FY+5
TTM
$7.12
FY+1
25
43%
$10.20
FY+2
24
11%
$11.35
FY+3
22
11%
$12.58
FY+4
11
14%
$14.38
FY+5
11
12%
$16.08

FCF per share

CAGR13.9%
TTMFY+1FY+2FY+3FY+4FY+5
TTM
$6.58
FY+1
10
16%
$5.55
FY+2
11
60%
$8.87
FY+3
11
11%
$9.85
FY+4
7
22%
$12.05
FY+5
6
5%
$12.61